Dr. Choueiri on adjuvant pembrolizumab for high-risk RCC at 30-month follow up
“These are consistent results that continue to demonstrate a disease-free survival benefit of pembrolizumab adjuvant versus placebo,” says Toni K. Choueiri, MD.
In this video, Toni K. Choueiri, MD, discusses the background, findings, and takeaways of the study, “Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Choueiri is a professor of medicine at Harvard Medical School, and an attending physician, director of the Genitourinary Oncology Disease Center, and director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
